Ned Sharpless is tapped to take on acting commissioner role following Gottlieb’s resignation.
One week following the surprise resignation of FDA Commissioner Scott Gottlieb, Norman E. (Ned) Sharpless, head of the National Cancer Institute (NCI), was named acting commissioner of FDA, according to media reports.
The announcement was confirmed by Health and Human Services Secretary Alex Azar at a congressional hearing on March 12, 2019.
Sharpless has served as the director of NCI since October 2017. He previously was director of the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center, served on the faculty at Harvard Medical School, and the University of North Carolina School of Medicine in the Departments of Medicine and Genetics.
He cofounded clinical-stage biotechnology companies G1 Therapeutics and HealthSpan Diagnostics, according to his NCI biography.
Source: NCI
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.